Merger with Merck Following its acquisition by Merck & Co., Inc., Cubist Pharmaceuticals presents a unique opportunity for cross-promotional strategies and collaboration with a larger pharmaceutical entity.

Recent Acquisition The acquisition of Triusrx for $700M showcases Cubist Pharmaceuticals' focus on expanding its portfolio, potentially opening doors for upselling and offering integrated solutions to a wider customer base.

High Revenue Potential With a revenue in the range of $100M - 1B, Cubist Pharmaceuticals holds significant revenue potential for partnerships, licensing deals, and direct sales efforts targeting pharmaceutical markets.

Competitive Landscape By comparing employee size and revenue with similar companies like Roche, Johnson & Johnson, and Pfizer, Cubist Pharmaceuticals can position itself strategically to compete effectively and penetrate new markets.

Financial Backing Despite lack of specific funding details, Cubist Pharmaceuticals' history of acquisitions and being part of the Merck group indicates stability and financial backing that can be leveraged to drive sales growth and innovation.